A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Aquestive Therapeutics, Inc.
AQST
$395M
Mkt Cap
$3.68
-2.39%
Aquestive Therapeutics, Inc. (AQST) has a 5-year average return on invested capital (ROIC) of -46.1%. This is below average and may indicate limited pricing power.
Aquestive Therapeutics, Inc. (AQST) has a market capitalization of $395M. It is classified as a small-cap stock.
Aquestive Therapeutics, Inc. (AQST) does not currently pay a regular dividend.
Aquestive Therapeutics, Inc. (AQST) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Aquestive Therapeutics, Inc. (AQST) reported annual revenue of $45 million in its most recent fiscal year, based on SEC EDGAR filings.
Aquestive Therapeutics, Inc. (AQST) has a net profit margin of -188.1%. The company is currently unprofitable.
Aquestive Therapeutics, Inc. (AQST) generated $-53 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. We are advancing our late stage non-device based epinephrine prodrug product candidate for the treatment of severe allergic reactions, including anaphylaxis, under the "Anaphylm™" trade name, and our AdrenaVerse™ epinephrine prodrug pipeline platform. We have four licensed commercialized products which are marketed by our licensees in the U.S. and around the world. We are the exclusive manufacturer of these licensed products. Aquestive also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 45M | 45M | 58M | 51M | 48M | 51M |
| Net Income | -84M | -84M | -44M | -7.9M | -54M | -71M |
| EPS | $-0.78 | $-0.78 | $-0.51 | $-0.13 | $-1.12 | $-1.85 |
| Free Cash Flow | -53M | -53M | -36M | -7.4M | -11M | -34M |
| ROIC | -35.0% | -44.3% | -30.3% | -26.3% | -73.7% | -55.9% |
| Gross Margin | 58.3% | 58.3% | 69.0% | 58.8% | 59.3% | - |
| Debt/Equity | 0.00 | -0.97 | -0.63 | -0.31 | -0.33 | -0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -71M | -71M | -31M | -15M | -42M | -35M |
| Operating Margin | -159.5% | -159.5% | -53.5% | -29.9% | -88.2% | -68.2% |
| ROE | 0.0% | 178.6% | 53.0% | 7.0% | 54.2% | 108.0% |
| Shares Outstanding | 107M | 107M | 87M | 61M | 49M | 38M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 67M | 67M | 53M | 46M | 51M | 48M | 51M | 58M | 45M | 45M |
| Gross Margin | N/A | N/A | 61.3% | 71.7% | N/A | 59.3% | 58.8% | 69.0% | 58.3% | 58.3% |
| R&D | 22M | 23M | 21M | 20M | 17M | 17M | 13M | 20M | 17M | 17M |
| SG&A | 25M | 72M | 64M | 56M | 53M | 53M | 32M | 50M | 80M | 80M |
| EBIT | N/A | -49M | -53M | -43M | -35M | -42M | -15M | -31M | -71M | -71M |
| Op. Margin | N/A | -72.6% | -100.1% | -93.6% | -68.2% | -88.2% | -29.9% | -53.5% | -159.5% | -159.5% |
| Net Income | -11M | -61M | -66M | -56M | -71M | -54M | -7.9M | -44M | -84M | -84M |
| Net Margin | -17.1% | -91.0% | -125.9% | -121.7% | -138.8% | -114.1% | -15.6% | -76.7% | -188.1% | -188.1% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 263K | 216K | 0 | 0 | 0 |
| Returns on Capital | ||||||||||
| ROIC | N/A | -56.3% | -179.1% | -166.8% | -55.9% | -73.7% | -26.3% | -30.3% | -44.3% | -35.0% |
| ROE | 27.3% | -608.9% | N/A | 204.3% | 108.0% | 54.2% | 7.0% | 53.0% | 178.6% | 0.0% |
| ROA | -26.5% | -94.4% | -80.1% | -78.9% | -113.0% | -91.4% | -13.7% | -55.6% | -64.0% | -52.2% |
| Cash Flow | ||||||||||
| Op. Cash Flow | 5.8M | -13M | -60M | -45M | -33M | -9.8M | -6.4M | -36M | -52M | -52M |
| Free Cash Flow | 3.8M | -15M | -61M | -46M | -34M | -11M | -7.4M | -36M | -53M | -53M |
| Owner Earnings | 2.1M | -46M | -70M | -55M | -43M | -17M | -10M | -44M | -61M | -61M |
| CapEx | 2.1M | 1.8M | 663K | 517K | 913K | 1.0M | 995K | 159K | 562K | 562K |
| Maint. CapEx | 3.8M | 3.2M | 2.9M | 3.4M | 3.0M | 2.4M | 1.3M | 718K | 548K | 548K |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14K | 14K |
| D&A | 3.8M | 3.2M | 2.9M | 3.4M | 3.0M | 2.4M | 1.3M | 718K | 548K | 548K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 0 | 30M | 7.1M | 6.6M | 6.8M | 4.4M | 2.7M | 7.1M | 7.6M | 7.6M |
| Debt Repayment | 0 | 0 | 50M | 23M | 0 | 0 | 52M | 23K | 26K | 26K |
| Balance Sheet | ||||||||||
| Net Debt | N/A | N/A | 21M | 23M | -25M | 12M | 9.4M | -34M | -89M | -89M |
| Cash & Equiv. | 17M | 61M | 49M | 32M | 28M | 27M | 24M | 72M | 121M | 121M |
| Long-Term Debt | N/A | N/A | 70M | 52M | 0 | 33M | 28M | 33M | 28M | 28M |
| Debt/Equity | -2.63 | 7.62 | -11.43 | -1.14 | -0.03 | -0.33 | -0.31 | -0.63 | -0.97 | 0.00 |
| Interest Coverage | N/A | -6.3 | -5.7 | -3.9 | -3.5 | -6.4 | -2.4 | -2.8 | -6.4 | -6.4 |
| Equity | -26M | 10M | -6.1M | -48M | -82M | -119M | -106M | -60M | -34M | -34M |
| Total Assets | 43M | 87M | 78M | 63M | 62M | 57M | 57M | 101M | 160M | 160M |
| Total Liabilities | 70M | 77M | 85M | 111M | 144M | 176M | 164M | 162M | 194M | 194M |
| Intangibles | 254K | 204K | 153K | 102K | 51K | 1.4M | 1.3M | 0 | 0 | 0 |
| Retained Earnings | -120M | -61M | -130M | -186M | -257M | -311M | -319M | -363M | -447M | -447M |
| Working Capital | 13M | 41M | 50M | 24M | 25M | 360K | 23M | 69M | 102M | 102M |
| Current Assets | 28M | 74M | 68M | 45M | 47M | 40M | 41M | 88M | 149M | 149M |
| Current Liabilities | 15M | 33M | 19M | 21M | 22M | 40M | 18M | 19M | 48M | 48M |
| Per Share Data | ||||||||||
| EPS | N/A | -2.96 | -2.61 | -1.66 | -1.85 | -1.12 | -0.13 | -0.51 | -0.78 | -0.78 |
| Owner EPS | N/A | -2.22 | -2.77 | -1.65 | -1.12 | -0.34 | -0.17 | -0.50 | -0.56 | -0.56 |
| Book Value | N/A | 0.49 | -0.24 | -1.44 | -2.15 | -2.44 | -1.76 | -0.70 | -0.31 | -0.31 |
| Cash Flow/Share | N/A | -0.63 | -2.37 | -1.35 | -0.86 | -0.20 | -0.11 | -0.41 | -0.49 | -0.77 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | N/A | 20.7M | 25.4M | 33.6M | 38.1M | 48.6M | 60.5M | 86.5M | 107.4M | 107.4M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4.7 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 12.7 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | 4.4 | 2.5 | 3.8 | 3.4 | 1.6 | 1.8 | 5.7 | N/A | 8.9 |
| FCF Yield | N/A | -11.6% | -43.3% | -24.0% | -22.7% | -28.9% | -6.1% | -11.8% | N/A | -13.4% |
| Market Cap | N/A | 128M | 140M | 192M | 149M | 38M | 121M | 305M | 0 | 395M |
| Avg. Price | N/A | 14.35 | 5.25 | 5.25 | 4.58 | 1.62 | 1.53 | 3.80 | 0.00 | 3.68 |
| Year-End Price | N/A | 6.16 | 5.53 | 5.70 | 3.92 | 0.77 | 2.00 | 3.52 | 0.00 | 3.68 |
Aquestive Therapeutics, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 61.4%.
Aquestive Therapeutics, Inc. (AQST) reported earnings per share (EPS) of $-0.78 in its most recent fiscal year.
Aquestive Therapeutics, Inc. (AQST) has a return on equity (ROE) of 178.6%. This indicates the company generates strong returns for shareholders.
Aquestive Therapeutics, Inc. (AQST) has a 5-year average gross margin of 61.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 9 years of financial data for Aquestive Therapeutics, Inc. (AQST), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Aquestive Therapeutics, Inc. (AQST) has a book value per share of $-0.31, based on its most recent annual SEC filing.